A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg with Placebo on Glycemic Control in Patients with Type 2 Diabetes on Basal Insulin Glargine
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Dulaglutide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-9
- Sponsors Eli Lilly and Company
- 01 Apr 2022 Results of post-hoc pooled analysis of six studies (AWARD-1, -2, -3, -6, -8 and -9) assessing association between treatment with dulaglutide and glycaemic variability in adult patients with type 2 diabetes mellitus, published in the Diabetes, Obesity and Metabolism.
- 16 Jun 2020 Results from AWARD- 2 and AWARD-9 presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 05 Jun 2018 Results of a post-hoc analysis of AWARD-1, AWARD-5, AWARD-8 and AWARD-9 clinical trials (n=1499) assessing effects of dulaglutide versus placebo on liver and glycaemic/metabolic measurements, published in the Diabetic Medicine